*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Fevipiprant is a potent, selective oral <strong>DP2 receptor antagonist</strong> developed for inflammatory disorders. Its molecular formula is <strong>C27H31N5O4S</strong> (CAS: 1389067-44-2), synthesized via advanced heterocyclic coupling.</p>
<h3>Application</h3>
<ul>
<li><strong>Respiratory Medicine:</strong> Investigated for chronic obstructive pulmonary disease (COPD) and asthma management.</li>
<li><strong>Dermatology:</strong> Potential therapeutic candidate for atopic dermatitis and psoriasis.</li>
<li><strong>Rheumatology:</strong> Targeting eosinophilic inflammation in autoimmune conditions.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly adhere to clinical trial protocols regarding dosage limits. Store raw material under inert atmosphere at <strong>-20°C</strong> to prevent degradation. Handle with appropriate PPE due to potential respiratory sensitization.</p>